Patents by Inventor Philip James Pye

Philip James Pye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12215110
    Abstract: Disclosed is a process for the preparation of certain intermediates, e.g. a process for preparing a compound of formula (I) wherein, R1, R2 and X1 are as defined in the description, and which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: February 4, 2025
    Assignee: Janssen Pharmaceutica NV
    Inventors: Philip James Pye, Andras Horvath, Cheng Yi Chen, Yuanyuan Yuan, Jinxiong Su, Shuo Wang, Simon Albert Wagschal
  • Publication number: 20240279227
    Abstract: The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV infection.
    Type: Application
    Filed: June 1, 2022
    Publication date: August 22, 2024
    Inventors: Chunliang LU, Gang DENG, Lianzhu LIU, Xiaoyu LI, Zhiguo LIU, Bingqing TANG, Wei CAI, Shane PLUNKETT, Philip James PYE, Lindsey Graham DERATT, Pierre Jean-Marie Bernard RABOISSON, Edgar JACOBY, Sandrine Céline GROSSE, Zhanling CHENG, Koen VANDYCK, Tim Hugo Maria JONCKERS, Scott D. KUDUK
  • Publication number: 20220235058
    Abstract: Disclosed is a process for the preparation of certain intermediates, e.g. process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, in an enantioenriched form, which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib.
    Type: Application
    Filed: May 20, 2020
    Publication date: July 28, 2022
    Inventors: Philip James PYE, Andras HORVATH, Laurent LEFORT, Bernardus KAPTEIN, Gerardus Karel Maria VERZIJL, Yuanyuan YUAN, Jinxiong SU
  • Publication number: 20220204516
    Abstract: Disclosed is a process for the preparation of certain intermediates, e.g. a process R for preparing a compound of formula (I) wherein, R1, R2 and X1 are as defined in the description, and which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib.
    Type: Application
    Filed: May 20, 2020
    Publication date: June 30, 2022
    Inventors: Philip James PYE, Andras HORVATH, Cheng Yi CHEN, Yuanyuan Yuan, Jinxiong SU, Shuo WANG, Simon Albert WAGSCHAL
  • Patent number: 10464939
    Abstract: The invention is directed to a triazolopyridazine compound of formula (I): N-oxides, pharmaceutically acceptable salts and solvates thereof, wherein D represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: November 5, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Blasius Furer, Ronaldus Arnodus Hendrika Joseph Gilissen, Ioannis Nicolaos Houpis, Lieven Meerpoel, Timothy Pietro Suren Perera, Philip James Pye
  • Publication number: 20190031670
    Abstract: The invention is directed to a triazolopyridazine compound of formula (I): N-oxides, pharmaceutically acceptable salts and solvates thereof, wherein D represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Application
    Filed: October 4, 2018
    Publication date: January 31, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Patrick Blasius Furer, Ronaldus Arnodus Hendrika Joseph Gilissen, Ioannnis Nicolaos Houpis, Lieven Meerpoel, Timothy Pietro Suren Perera, Philip James Pye
  • Patent number: 10138246
    Abstract: The invention is directed to a triazolopyridazine compound of formula (I), N-oxides, pharmaceutically acceptable salts and solvates thereof, wherein D represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: November 27, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Blasius Furer, Ronaldus Arnodus Hendrika Joseph Gilissen, Ioannnis Nicolaos Houpis, Lieven Meerpoel, Timothy Pietro Suren Perera, Philip James Pye
  • Publication number: 20170267684
    Abstract: The invention is directed to a triazolopyridazine compound of formula (I), N-oxides, pharmaceutically acceptable salts and solvates thereof, wherein D represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Application
    Filed: December 3, 2015
    Publication date: September 21, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Patrick Blasius Furer, Ronaldus Arnodus Hendrika Joseph Gilissen, Ioannnis Nicolaos Houpis, Lieven Meerpoel, Timothy Pietro Suren Perera, Philip James Pye
  • Patent number: 8569494
    Abstract: Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: October 29, 2013
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Roy L. Harris, John Sapienza, Graziella Shevlin, Patrick Papa, Branden Gingsee Lee, Garrick Packard, Jingjing Zhao, Patrick Anthony Jokiel, Deborah Mortensen, Jennifer Riggs, Juan Antonio Gamboa, Marie Georges Beauchamps, Matthew Michael Kreilein, Mohit Atul Kothare, Sophie Perrin-Ninkovic, Philip James Pye, William Wei-Hwa Leong, Jan Elsner, Anusuya Choudhury